Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology

Трансплантация гемопоэтических клеток, версия 3.2025, Клинические руководства NCCN по онкологии
Mark A. Schroeder, Areej El‐Jawahri, Yago Nieto, Omer Jamy, Marco Mielcarek, Antonio Di Stasi, Genovefa A. Papanicolaou, Thomas Martin, Vincent T. Ho, Alison W. Loren, Javier Bolaños‐Meade, Jonathan E. Brammer, Meredith Cowden, Hany Elmariah, Krishna Gundabolu, Jonathan A. Gutman, Rasmus T. Hoeg, Mitchell E. Horwitz, Adetola A. Kassim, Mohamed Kharfan Dabaja, Lauren Lee, Aaron C. Logan, Christina Luszcak, John Magenau, Varun Mittal, Jonathan Moreira, Lori Muffly, Ryotaro Nakamura, Mariam Nawas, Cameron Ninos, Caspian Oliai, Joseph A. Pidala, Brion Randolph, Jeffrey Tessier, Jeffrey Topal, Dimitrios Tzachanis, Asya Varshavsky‐Yanovsky, Frankie Jones, Katie Stehman
2025-10-01

Hematopoietic Cell Transplantation (HCT)allogeneic HCTautologous HCTgraft-versus-host disease (GVHD)pretransplant recipient evaluation
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation (HCT) provide expert, multidisciplinary recommendations for autologous and allogeneic HCT based on current evidence. The NCCN Guidelines focus on pretransplant recipient evaluation, hematopoietic cell mobilization, conditioning, and the diagnosis and management of graft-versus-host disease (GVHD), a common complication of allogeneic HCT that is associated with significant morbidity. This selection from the NCCN Guidelines for HCT focuses on the diagnosis, workup, and management of acute and chronic GVHD, as well as important supportive care considerations.
1
Guidelines emphasize pretransplant recipient evaluation, hematopoietic cell mobilization, and conditioning as critical components of HCT care.
2
Important supportive care considerations related to HCT and GVHD management are included in the guideline selection.
3
NCCN Guidelines for Hematopoietic Cell Transplantation (Version 3.2025) provide multidisciplinary, evidence-based recommendations for autologous and allogeneic HCT.
4
The guidance focuses on diagnosis, workup, and management of acute and chronic graft-versus-host disease (GVHD), highlighting GVHD as a common, morbid complication of allogeneic HCT.

Hematopoietic cell transplantation (HCT) clinical practice for autologous and allogeneic transplants

Diagnosis, workup, and management of acute and chronic graft-versus-host disease (GVHD) and related pretransplant evaluation, mobilization, conditioning, and supportive care considerations

Publication Details
Publication Date
2025-10-01
Journal
Publisher
ISSN
Cited by
10
Access Type
Author Information
Authors
Mark A. Schroeder
Areej El‐Jawahri
Yago Nieto
Omer Jamy
Marco Mielcarek
Antonio Di Stasi
Genovefa A. Papanicolaou
Thomas Martin
Vincent T. Ho
Alison W. Loren
Javier Bolaños‐Meade
Jonathan E. Brammer
Meredith Cowden
Hany Elmariah
Krishna Gundabolu
Jonathan A. Gutman
Rasmus T. Hoeg
Mitchell E. Horwitz
Adetola A. Kassim
Mohamed Kharfan Dabaja
Lauren Lee
Aaron C. Logan
Christina Luszcak
John Magenau
Varun Mittal
Jonathan Moreira
Lori Muffly
Ryotaro Nakamura
Mariam Nawas
Cameron Ninos
Caspian Oliai
Joseph A. Pidala
Brion Randolph
Jeffrey Tessier
Jeffrey Topal
Dimitrios Tzachanis
Asya Varshavsky‐Yanovsky
Frankie Jones
Katie Stehman
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%